Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Melanoma immunotherapy using mature DCs expressing the constitutive proteasome
Jens Dannull, … , Douglas S. Tyler, Scott K. Pruitt
Jens Dannull, … , Douglas S. Tyler, Scott K. Pruitt
Published June 24, 2013
Citation Information: J Clin Invest. 2013;123(7):3135-3145. https://doi.org/10.1172/JCI67544.
View: Text | PDF
Clinical Research and Public Health Oncology Article has an altmetric score of 52

Melanoma immunotherapy using mature DCs expressing the constitutive proteasome

  • Text
  • PDF
Abstract

Background. Many cancers, including melanoma, exclusively express constitutive proteasomes (cPs) and are unable to express immunoproteasomes (iPs). In contrast, mature DCs used for immunotherapy exclusively express iPs. Since proteasomes generate peptides presented by HLA class I molecules, we hypothesized that mature melanoma antigen–loaded DCs engineered to process antigens through cPs would be superior inducers of antimelanoma immunity in vivo.

Methods. Subjects with metastatic melanoma were vaccinated with mature DCs transfected with RNAs encoding melanoma antigens MART1, MAGE-3, gp100, and tyrosinase. These DCs were derived from monocytes that were untransfected (Arm A; n = 4), transfected with control siRNA (Arm B; n = 3), or transfected with siRNAs targeting the 3 inducible iP subunits (Arm C; n = 5).

Results. Vaccination stimulated antigen-specific T cell responses in all subjects, which peaked after 3–4 vaccinations, but remained elevated in Arm C subjects. Also in Arm C, circulating melanoma cell levels (as detected by quantitative PCR) fell, and T cell lytic activity against autologous melanoma was induced. In HLA-A2+ subjects, CD8+ T cells that bound tetramers loaded with cP-derived melanoma antigenic peptides were found in the peripheral blood only in Arm C subjects. Of 2 subjects with active disease (both in Arm C), one had a partial clinical response, while the other, who exhibited diffuse dermal and soft tissue metastases, had a complete response.

Conclusion. These results suggest that the efficacy of melanoma DC–based immunotherapy is enhanced when tumor antigen–loaded DCs used for vaccination express cPs.

Trial registration. Clinicaltrials.gov NCT00672542.

Funding. Duke Clinical Research Institute/Duke Translational Medicine Institute, Duke Melanoma Consortium, and Duke University Department of Surgery.

Authors

Jens Dannull, N. Rebecca Haley, Gary Archer, Smita Nair, David Boczkowski, Mark Harper, Nicole De Rosa, Nancy Pickett, Paul J. Mosca, James Burchette, Maria A. Selim, Duane A. Mitchell, John Sampson, Douglas S. Tyler, Scott K. Pruitt

×

Total citations by year

Year: 2024 2023 2021 2020 2019 2018 2017 2016 2015 2014 2013 Total
Citations: 2 1 2 6 2 1 1 4 2 7 1 29
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (29)

Title and authors Publication Year
Cancer mRNA vaccines: clinical advances and future opportunities.
Sayour EJ, Boczkowski D, Mitchell DA, Nair SK
Nature reviews. Clinical oncology 2024
LncRNAs in melanoma phenotypic plasticity: emerging targets for promising therapies
Beatriz Cristina Biz T, Carolina de Sousa CS, Frank John S, Miriam Galvonas J
RNA Biology 2024
A Comprehensive Review of Small Interfering RNAs (siRNAs): Mechanism, Therapeutic Targets, and Delivery Strategies for Cancer Therapy.
Zhang J, Chen B, Gan C, Sun H, Zhang J, Feng L
International Journal of Nanomedicine 2023
Recent Advances in Oligonucleotide Therapeutics in Oncology
H Xiong, RN Veedu, SD Diermeier
International journal of molecular sciences 2021
Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics
R Cuciniello, S Filosa, S Crispi
Journal of Experimental & Clinical Cancer Research 2021
Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells—An Update
J Dörrie, N Schaft, G Schuler, B Schuler-Thurner
Pharmaceutics 2020
Neo-Antigen mRNA Vaccines
A Esprit, W de Mey, RB Shahi, K Thielemans, L Franceschini, K Breckpot
Human vaccines 2020
Ribonucleic Acid Engineering of Dendritic Cells for Therapeutic Vaccination: Ready ‘N Able to Improve Clinical Outcome?
Y Willemen, M Versteven, M Peeters, ZN Berneman, EL Smits
Cancers 2020
Dissimilar Appearances Are Deceptive–Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma
L Linck-Paulus, C Hellerbrand, AK Bosserhoff, P Dietrich
Cells 2020
Comprehensive Survey of Clinical Trials Registration for Melanoma Immunotherapy in the ClinicalTrials.gov
YB Wang, G Lv, FH Xu, LL Ma, YM Yao
Frontiers in pharmacology 2020
NADPH oxidase correction by mRNA transfection of apheresis granulocytes in chronic granulomatous disease
SS Ravin, J Brault, RJ Meis, L Li, N Theobald, AC Bonifacino, H Lei, TQ Liu, S Koontz, C Corsino, MA Zarakas, JV Desai, AB Clark, U Choi, ME Metzger, K West, SL Highfill, E Kang, DB Kuhns, MS Lionakis, DF Stroncek, CE Dunbar, JF Tisdale, RE Donahue, GA Dahl, HL Malech
Blood Advances 2020
Proteasomes and Several Aspects of Their Heterogeneity Relevant to Cancer
AV Morozov, VL Karpov
Frontiers in Oncology 2019
Releasing the Immune System Brakes Using siRNAs Enhances Cancer Immunotherapy
M Sioud
Cancers 2019
Nuclear Receptor Nur77 Deficiency Alters Dendritic Cell Function
N Tel-Karthaus, ED Kers-Rebel, MW Looman, H Ichinose, CJ de Vries, M Ansems
Frontiers in immunology 2018
Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen–specific CTLs
MC Brown, EK Holl, D Boczkowski, E Dobrikova, M Mosaheb, V Chandramohan, DD Bigner, M Gromeier, SK Nair
Science Translational Medicine 2017
Direct Delivery of Antigens to Dendritic Cells via Antibodies Specific for Endocytic Receptors as a Promising Strategy for Future Therapies
C Lehmann, L Heger, G Heidkamp, A Baranska, J Lühr, A Hoffmann, D Dudziak
Human vaccines 2016
Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19
M Carlsten, E Levy, A Karambelkar, L Li, R Reger, M Berg, MV Peshwa, RW Childs
Frontiers in immunology 2016
Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma
K Woods, AJ Knights, M Anaka, RB Schittenhelm, AW Purcell, A Behren, J Cebon
Journal for ImmunoTherapy of Cancer 2016
Dendritic cell vaccines for melanoma: past, present and future
RO Dillman, GI Nistor, AN Cornforth
Melanoma Management 2016
Dendritic Cell-Based Vaccination in Cancer: Therapeutic Implications Emerging from Murine Models
SM Keon, MÃ Ruiz, S Gazzaniga, R Wainstok
Frontiers in immunology 2015
Dendritic cells pulsed with Hsp70 and HBxAg induce specific antitumor immune responses in hepatitis�B virus‑associated hepatocellular carcinoma
H Wang, F Feng, XP Wang, RS Wang, Y Wu, MG Zhu, H Zhang, ZX Zhuang
Molecular medicine reports 2015
Messenger RNA (mRNA) nanoparticle tumour vaccination
KK Phua, SK Nair, KW Leong
Nanoscale 2014
Trial watch: Dendritic cell-based anticancer therapy
N Bloy, J Pol, F Aranda, A Eggermont, I Cremer, WH Fridman, J Fučíková, J Galon, E Tartour, R Spisek, MV Dhodapkar, L Zitvogel, G Kroemer, L Galluzzi
OncoImmunology 2014
Antibody therapies for melanoma: New and emerging opportunities to activate immunity (Review)
S Malas, M Harrasser, KE Lacy, SN Karagiannis
Oncology reports 2014
Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity
KK Phua, HF Staats, KW Leong, SK Nair
Scientific Reports 2014
Proteasome Subtypes and Regulators in the Processing of Antigenic Peptides Presented by Class I Molecules of the Major Histocompatibility Complex
N Vigneron, BV Eynde
Biomolecules 2014
Novel anti-melanoma treatment: focus on immunotherapy
MZ Hao, WY Zhou, XL Du, KX Chen, GW Wang, Y Yang, JL Yang
Chinese journal of cancer 2014
Pathways and therapeutic targets in melanoma
Shtivelman E, Davies MA, Hwu P, Yang J, Lotem M, Oren M, Flaherty KT, Fisher DE
Oncotarget 2014
Human Vaccines & Immunotherapeutics: News
Riedmann EM
Human Vaccines & Immunotherapeutics 2013

← Previous 1 2 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 4 news outlets
Blogged by 1
Posted by 4 X users
Referenced in 2 patents
On 2 Facebook pages
Referenced in 1 Wikipedia pages
97 readers on Mendeley
See more details